Thompson Davis & Co’s Core Laboratories CLB Stock Holding History

Thompson Davis & Co’s Portfolio CLB Stock Details CLB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-267	Closed	-$26K	–	749
2017 Q3	$26K	Buy	267 +81	+44%	+$7.85K	0.05%	392
2017 Q2	$19K	Hold	186	–	–	0.03%	477
2017 Q1	$21K	Hold	186	–	–	0.03%	468
2016 Q4	$22K	Hold	186	–	–	0.04%	464
2016 Q3	$21K	Hold	186	–	–	0.04%	462
2016 Q2	$23K	Sell	186 -92	-33%	-$11.1K	0.04%	421
2016 Q1	$31K	Sell	278 -45	-14%	-$4.67K	0.05%	323
2015 Q4	$35K	Sell	323 -1,000	-76%	-$114K	0.05%	320
2015 Q3	$132K	Buy	1,323 +962	+266%	+$105K	0.18%	126
2015 Q2	$41K	Sell	361 -12	-3%	-$1.46K	0.05%	352
2015 Q1	$39K	Buy	373 +51	+16%	+$5.43K	0.05%	343
2014 Q4	$39K	Buy	322 +73	+29%	+$9.59K	0.05%	329
2014 Q3	$36K	Buy	+249	New	+$38.4K	0.05%	333

Other funds holding CLB

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SGA

Sustainable Growth Advisers Stamford, Connecticut $10.2B AUM 1.48% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

EIP

Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return

Thompson Davis & Co's CLB Position: Q4 2017 in Review

Thompson Davis & Co sold out of Core Laboratories (CLB) in Q4 2017, closing a stake of 267 shares — an estimated $26K sold.

Thompson Davis & Co first reported a position in CLB in Q3 2014 and held it in 13 quarters. The position peaked at $132K in Q3 2015. 356 funds tracked by Wall St. Rank hold CLB as of Q4 2017.

Thompson Davis & Co reported no remaining Core Laboratories position as of Q4 2017 after selling out during the quarter.
Thompson Davis & Co sold 267 Core Laboratories shares in Q4 2017, an estimated $26K.
Thompson Davis & Co first reported a position in Core Laboratories in Q3 2014 and held it in 13 quarters.
Thompson Davis & Co's Core Laboratories position peaked at $132K in Q3 2015.
356 funds tracked by Wall St. Rank held Core Laboratories as of Q4 2017.

Based on Thompson Davis & Co's 13F filing for Q4 2017, filed 5 Feb 2018.